Please ensure Javascript is enabled for purposes of website accessibility

Better Late Than Never: Sanofi and GlaxoSmithKline Start Coronavirus Vaccine Clinical Trial Program

By Brian Orelli, PhD - Sep 3, 2020 at 2:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With competitors already in phase 3 development, the European drugmakers are just now starting a phase 1/2 clinical trial.

Sanofi (SNY 2.19%) may be late to the coronavirus vaccine game, but it has a good excuse for finally launching the first phase of its clinical trial program: The French drugmaker is using a traditional protein-based approach to develop its coronavirus vaccine.

Moderna (MRNA -0.37%) and BioNTech (BNTX 1.11%) -- both more than halfway through enrolling their respective phase 3 clinical trials -- were able to move more rapidly from concept to a vaccine candidate ready for clinical trials because they're using a new approach called messenger RNA (mRNA). The technology allows for easy manufacturing of an mRNA that codes for a protein for the coronavirus. Then the patient's cells do the hard work, using the mRNA to express the viral protein inside the patient.

The more traditional approach that Sanofi has taken required the company to figure out how to manufacture and purify the viral protein expressed in cells in a bioreactor. Proteins are a lot more variable than mRNA, making the manufacturing setup a time-consuming process.

Gloved hands giving an injection into a shoulder

Image source: Getty Images.

In April, Sanofi enlisted the help of GlaxoSmithKline (GSK 0.84%), which has an established pandemic adjuvant technology designed to boost the immune response to the vaccine. The companies expect to be able to manufacture enough of the vaccine and the adjuvant to create 1 billion doses in 2021.

Sanofi, which is leading the clinical development, plans to enroll 440 participants in the phase 1/2 study, with initial data expected in December 2020. At that point, Sanofi and GlaxoSmithKline hope to be able to start a phase 3 clinical trial, which would potentially allow the duo to apply for regulatory approval in the first half of 2021.

While taking longer in preclinical development, Sanofi's protein-based technique is a proven technology that is also used in its flu vaccine, which will hopefully increase the likelihood of success if Moderna's and BioNTech's newer technology stumbles.

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$44.37 (2.19%) $0.95
GSK Stock Quote
$36.03 (0.84%) $0.30
Moderna, Inc. Stock Quote
Moderna, Inc.
$171.18 (-0.37%) $0.63
BioNTech SE Stock Quote
BioNTech SE
$160.35 (1.11%) $1.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.